Table 2.
Comparison of laboratory indices in the two groups after 12 months follow-up
| Patients | RTX + TAC | TAC | P value |
|---|---|---|---|
| Rituximab dose (mg) (mean ± SD) | 219.2±112.9 | 0.00 | 0.00 |
| Proteinuria (g/24 h) (mean ± SD) | 2158.1±2412.9 | 3732.1±3190.3 | 0.037 |
| Albumin (g/L) (mean ± SD) | 36.45±8.04 | 32.08±8.65 | 0.046 |
| Creatinine (umol/L) (mean ± SD) | 77.81±19.01 | 92.49±23.01 | 0.011 |
| eGFR (mL/min/1.73 m2) (mean ± SD) | 98.25±25.06 | 81.74±21.50 | 0.006 |
| PLA2R positive rates (positive/total) (%) | 2/26 (7.69) | 7/41 (17.1) | 0.465 |
| Median time for achieving partial response (month) (IQR) | 3 (1.0-6.0) | 3 (1.5-8.25) | 0.272 |
| Time for antibody to turn negative (month) (IQR) | 3.13 (1.97-7.25) | 4.89 (2.65-7.89) | 0.021 |
| 24 h-proteinuria reduction of non-responsive iMN | -1585±2842 | 588.7±2316.3 | 0.033 |
eGFR: Estimated glomerular filtration rate; P value <0.05 indicates statistically significant difference; RTX: Rituximab; TAC: Tacrolimus.